Clinical experiences with hydrocortisone 17-butyrate

Area of Science:

• Dermatology
• Pharmacology

Background:

• Eczematous dermatitis, atopic dermatitis, and psoriasis are common inflammatory skin conditions.
• Topical corticosteroids are a mainstay treatment for these dermatoses.
• Comparing the efficacy of different corticosteroids is crucial for optimal patient management.

Purpose of the Study:

• To compare the clinical efficacy of hydrocortisone 17-butyrate (HC 17-B) with triamcinolone acetonide (TA) and hydrocortisone 21-acetate (HA) in patients with acute eczematous dermatitis, atopic dermatitis, and psoriasis vulgaris.

Main Methods:

• A double-blind, comparative study involving 29 dermatological departments.
• Patients with acute eczematous dermatitis, atopic dermatitis, and psoriasis vulgaris were included.
• Treatment efficacy was evaluated after a 7-day observation period using chi-squared and Armitage tests.

Main Results:

• In acute eczematous dermatitis, HC 17-B was superior to placebo and equivalent to TA.
• For atopic dermatitis, HC 17-B outperformed placebo and HA, and was comparable to TA.
• HC 17-B demonstrated superiority over placebo, HA, and TA in treating psoriasis vulgaris.

Conclusions:

• Hydrocortisone 17-butyrate (HC 17-B) exhibits significant efficacy across various dermatological conditions.
• HC 17-B is a potent topical corticosteroid, showing comparable or superior results to other agents like TA and HA.
• The findings support the use of HC 17-B as an effective treatment option for eczema and psoriasis.